Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone added to conventional antifungal therapy for cryptococcal meningitis
RBR-9fv3f4Not yet recruiting
- Sponsor
- National Council for Scientific and Technological Development
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of pioglitazone in cryptococcal meningitis (3 arms), sponsored by National Council for Scientific and Technological Development. Primary endpoint: Cerebrospinal fluid culture negativity. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
pioglitazone
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on RBR-9fv3f4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9fv3f4.